# US 2016/0252521 A1 · Method for determining high-mannose glycans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252521 A1
- Document ID: US20160252521A1
- Status: Published application
- Kind: A1
- Application number: 15/030,367
- Filed: 2014-10-17
- Published: 2016-09-01
- Earliest claimed: 2013-10-18
- Assignees: Genovis AB
- Applicants: Genovis AB
- Inventors: Fredrik OLSSON; Stephen Georg BJOK; Maria NORDGREN; Sarah FREDRIKSSON
- Web page: https://patentgrep.com/patent/US20160252521A1

## CPC

- G01N 33/6857: {Antibody fragments}
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for analysing molecules comprising immunoglobulin Fc regions for the presence or absence of high-mannose glycans, and to for carrying out such methods.

## Claims

### Claim 1

A method for determining the presence or absence of high-mannose glycans attached to a molecule comprising an immunoglobulin Fc region, the method comprising:
(a) contacting a sample of said molecule with an endoglycosidase polypeptide capable of cleaving high-mannose glycans to form a mixture; and
(b) analysing the resulting mixture for the presence or absence of high-mannose glycans and/or Fc regions containing high-mannose glycans; and optionally
(c) quantifying a proportion of molecules in the sample which contain high-mannose glycans by calculating a quantity of high-mannose glycans in the mixture relative to a total quantity of glycans in the mixture.

### Claim 2 (depends on 1)

The method of claim 1, wherein prior to step (a) the sample is contacted with an endoglycosidase polypeptide not capable of cleaving high-mannose glycans, optionally wherein molecules comprising Fc regions are isolated from the resulting mixture and used in step (a).

### Claim 3 (depends on 1)

The method of claim 1, further comprising:
(d) contacting a second sample of said molecule with an endoglycosidase polypeptide not capable of cleaving high-mannose glycans to form a second mixture;
(e) analysing the resulting second mixture for the presence or absence of high-mannose glycans and/or Fc regions containing high-mannose glycans; and
(f) comparing the results of the analysis in (b) to the results of the analysis in (e) to thereby determine the presence or absence of molecules which contain high-mannose glycans.

### Claim 4 (depends on 3)

The method of claim 3, wherein step (e) further comprises quantifying a proportion of molecules in the second sample which contain high-mannose glycans.

### Claim 5 (depends on 1)

The method claim 1, wherein
the endoglycosidase polypeptide capable of cleaving high-mannose glycans comprises the sequence of SEQ ID NO: 1, or a variant thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the variant of said sequence is an amino acid sequence having at least 80% identity to said sequence or a fragment comprising up to 800 contiguous amino acids of said sequence.

### Claim 7 (depends on 1)

The method of claim 1, wherein the molecule comprising an Fc region is an antibody or fragment thereof, or an Fc-fusion protein.

### Claim 8 (depends on 7)

The method of claim 7, wherein the Fc region is of isotype IgG.

### Claim 9 (depends on 7)

The method of claim 7, wherein the antibody is a monoclonal antibody which is chimeric, human or humanised.

### Claim 10 (depends on 9)

The method of claim 9, wherein the mixture resulting from contacting the sample with the endoglycosidase is contacted with an IgG cysteine protease prior to any analysis step.

### Claim 11 (depends on 1)

The method of claim 1, wherein analysing the resulting mixture comprises determining the molecular weight of at least one molecule in the mixture.

### Claim 12 (depends on 1)

The method of claim 1, which comprises comparing a result obtained from applying said method to a first batch of the molecule to a result obtained from applying said method to a second batch of the molecule.

### Claim 13

A kit comprising a polypeptide comprising the sequence of SEQ ID NO: 1, or a variant thereof, and optionally
(a) means for detecting high-mannose glycans and/or high-mannose containing IgG molecules; and/or (b) instructions to detect high-mannose glycans and/or high-mannose containing IgG molecules.

### Claim 14 (depends on 13)

The kit of claim 13, additionally comprising a polypeptide comprising the sequence of SEQ ID NO: 2, or a variant thereof.

### Claim 15 (depends on 3)

The method of claim 3, wherein the endoglycosidase polypeptide not capable of cleaving high-mannose glycans comprises the sequence of SEQ ID NO: 2, or a variant thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein a variant of a said sequence is an amino acid sequence having at least 80% identity to said sequence or a fragment comprising up to 800 contiguous amino acids of said sequence.

### Claim 17 (depends on 8)

The method of claim 8, wherein the IgG is of human subclass IgG1, IgG2, IgG3 or IgG4.

### Claim 18 (depends on 11)

The method of claim 11, wherein the molecular weight of at least one molecule in the mixture is determined using high performance liquid chromatography (HPLC) and/or mass spectrometry.

### Claim 19 (depends on 12)

The method of claim 12, wherein the molecule is a therapeutic antibody or Fc fusion protein.

### Claim 20

A method for determining the presence or absence of high-mannose glycans attached to a molecule comprising an immunoglobulin Fc region, the method comprising:
(a) contacting a sample of a first batch of said molecule with an endoglycosidase polypeptide capable of cleaving high-mannose glycans;
(b) analysing the sample of the first batch for the presence, absence, or quantity of high-mannose glycans and/or Fc regions containing high-mannose glycans;
(c) contacting a sample of a second batch of said molecule with an endoglycosidase polypeptide capable of cleaving high-mannose glycans;
(d) analysing a the sample of the second batch for the presence, absence, or quantity of high-mannose glycans and/or Fc regions containing high-mannose glycans; and
(e) comparing a result obtained from analyzing the sample of the first batch of said molecule to a result obtained from analyzing the sample of the second batch of said molecule.
